Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 9,549 $ 17,116
Prepaid expenses and other current assets 559 827
Total Current Assets 10,108 17,943
Property and equipment, net 665 872
Deposits and other assets 23 23
Total Assets 10,796 18,838
Current Liabilities:    
Accounts payable 879 2,020
Accrued expenses 1,485 1,526
Warrant liabilities 19 4,083
Accrued employee benefits 1,434 2,074
Deferred rent 97 90
Total Current Liabilities 3,914 9,793
Long term deferred rent 329 402
Total Liabilities 4,243 10,195
Series A convertible preferred stock, $0.001 par value; 10,000,000 and zero shares authorized; 120,000 issued and outstanding 12,234 12,053
Stockholders' Deficit:    
Common stock, $0.001 par value; 200,000,000 and 10,000,000 shares authorized, 5,346,674 and 3,675,668 issued and 5,344,346 and 3,673,340 outstanding 5 4
Additional paid-in capital 200,807 192,670
Accumulated deficit (204,545) (194,170)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit (3,733) (1,496)
Non-controlling interest (1,948) (1,914)
Total Stockholders' Deficit (5,681) (3,410)
Total Liabilities and Stockholders' Deficit $ 10,796 $ 18,838